NEW YORK – MIT spinout C2Sense said Wednesday it completed the second closing of its $8 million Series B round, which will fund initial clinical and usability studies to support its Halo lateral flow assay reader and app.
The Halo platform uses compact, reusable readers with commercially available colorimetric or fluorescent rapid tests and delivers test results to a user's phone via Bluetooth connection and a company app. The reader can perform single-target or multiplexed detection, according to a product overview from the Massachusetts-based company.
The firm said Wednesday that the platform provides a pathway for developers and manufacturers to create rapid tests for point-of-care, point-of-need, and over-the-counter use.
C2Sense CEO Jason Cox said in a statement, "We are committed to creating low-cost, open-sourced, digitally connected diagnostic solutions so that all people have access to a wide variety of rapid tests and reliable results regardless of income or location."
Company officials said in a study published in April 2022 in Frontiers in Public Health that the reader components and assembly cost less than $100.